GSK
4 years ago ⋅ English ⋅ 15 min read
Newsroom
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients

For media and investors onlyIssued: London UK and San Francisco US- Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalisation or death in high-risk adult out... Read More
GSK
4 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK announced as a Principal Partner of COP26 UN Climate Change Conference

For media and investors only- Builds on and contributes to company target of being carbon net zero and nature net positive by 2030- As Principal Partner, GSK will drive action on climat... Read More
GSK
4 years ago ⋅ English ⋅ 11 min read
Newsroom
EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19

For media and investors only- Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early t... Read More
GSK
4 years ago ⋅ English ⋅ 1 min read
Newsroom
GSK announces sale of stake in Innoviva Inc

Shares to be sold back to Innoviva at $12.25 per shareFor media and investors onlyIssued: 20 May 2021, London UKGlaxoSmithKline has agreed with Innoviva, Inc (“Innoviva”) -... Read More
GSK
4 years ago ⋅ English ⋅ 5 min read
Newsroom
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

For media and investors only- Similar antibody response in adults and in the elderly after two doses- Neutralizing antibody responses were ten times higher than in people recovering fro... Read More
GSK
4 years ago ⋅ English ⋅ 5 min read
Newsroom
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

For media and investors only- Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups- High immune response after a si... Read More